February 15, 2022 02:01 PM ESTUpdated February 18, 04:52 AM

Benefits of Lilly's diabetes candidate tirzepatide aren't better than other diabetes drugs, says watchdog ICER

Paul Schloesser

Associate Editor

Eli Lilly’s tirzepatide — the type 2 diabetes candidate and Trulicity’s heir apparent, projected to be a megablockbuster drug within the next five years …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Benefits of Lilly's diabetes candidate tirzepatide aren't better than other diabetes drugs, says watchdog ICER

Paul Schloesser

Associate Editor

Sign up to read this article for free.

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings

Ben­e­fits of Lil­ly's di­a­betes can­di­date tirzepatide aren't bet­ter than oth­er di­a­betes drugs, says watch­dog ICER

Paul Schloesser

Associate Editor

Sign up to read this article for free.

more like this

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Benefits of Lilly's diabetes candidate tirzepatide aren't better than other diabetes drugs, says watchdog ICER

The Endpoints 2024 winners and losers list: Who was up and who was down in biopharma

CagriSema’s weight loss data disappointed. What does Novo do next?

CMS explains what went into its first round of drug price negotiations

Updated: Novo’s 23% weight loss with CagriSema falls short of high expectations, new trial planned

Deerfield wins fight to acquire Singular Genomics, beating out Tang Capital’s Concentra

Vertex gets 'vanza triple' approval and Trikafta expansion — with boxed warnings